Pharmaceutical firm Roche has said Avastin® (bevacizumab) has been approved in Europe for treating patients with some forms of lung cancer.
The drug has been approved to treat advanced nonsmall-cell lung cancer (NSCLC), the most common form of the disease that kills more than 3,000 people every day worldwide.
The company said Avastin is the only first-line therapy which shows improved survival benefits beyond one year in patients suffering from the disease.
A statement added: “We will continue to work with European authorities to make Avastin available to as many patients with NSCLC as possible.”
In a separate move, the drug giant said its US partner Genentech has resubmitted an application to the FDA to get approval for Avastin to be used in treating breast cancer.
The resubmission, based on a phase III trial, means there will now be a six-month review period by the FDA.
Copyright © PA Business 2007